JP2020535791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535791A5 JP2020535791A5 JP2020509099A JP2020509099A JP2020535791A5 JP 2020535791 A5 JP2020535791 A5 JP 2020535791A5 JP 2020509099 A JP2020509099 A JP 2020509099A JP 2020509099 A JP2020509099 A JP 2020509099A JP 2020535791 A5 JP2020535791 A5 JP 2020535791A5
- Authority
- JP
- Japan
- Prior art keywords
- cardiomyocytes
- derived
- stem cell
- cells
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 93
- 210000000130 stem cell Anatomy 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 48
- 239000000758 substrate Substances 0.000 claims description 31
- 108700011259 MicroRNAs Proteins 0.000 claims description 23
- 108091042844 let-7i stem-loop Proteins 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 239000002679 microRNA Substances 0.000 claims description 19
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 17
- 239000005495 thyroid hormone Substances 0.000 claims description 17
- 229940036555 thyroid hormone Drugs 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 9
- 230000002107 myocardial effect Effects 0.000 claims description 9
- 230000000747 cardiac effect Effects 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 4
- 206010048610 Cardiotoxicity Diseases 0.000 claims description 3
- 231100000259 cardiotoxicity Toxicity 0.000 claims description 3
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 210000004165 myocardium Anatomy 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 description 16
- 208000021642 Muscular disease Diseases 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 6
- 201000009623 Myopathy Diseases 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 230000010349 pulsation Effects 0.000 description 2
- 210000002235 sarcomere Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546438P | 2017-08-16 | 2017-08-16 | |
| US62/546,438 | 2017-08-16 | ||
| PCT/IB2018/056169 WO2019035032A2 (en) | 2017-08-16 | 2018-08-16 | COMPOSITIONS AND METHODS FOR ENHANCING THE MATURATION OF HEALTHY AND ILL HEART CARDIOMYCYTES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535791A JP2020535791A (ja) | 2020-12-10 |
| JP2020535791A5 true JP2020535791A5 (enExample) | 2021-09-30 |
Family
ID=65362375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020509099A Pending JP2020535791A (ja) | 2017-08-16 | 2018-08-16 | 健常および病変心筋細胞の成熟状態を増強するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200224168A1 (enExample) |
| EP (1) | EP3664821A4 (enExample) |
| JP (1) | JP2020535791A (enExample) |
| KR (1) | KR20200039707A (enExample) |
| CN (1) | CN111246863A (enExample) |
| WO (1) | WO2019035032A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111629738A (zh) * | 2017-12-08 | 2020-09-04 | 华盛顿大学 | 检测和促进心磷脂重塑和心肌细胞成熟的方法和组合物以及治疗线粒体功能障碍的相关方法 |
| US20220152117A1 (en) * | 2019-03-18 | 2022-05-19 | University Of Washington | Methods of promoting cellular maturation with ampk activators |
| WO2022010049A1 (ko) * | 2020-07-09 | 2022-01-13 | 주식회사 티앤알바이오팹 | 인간 전분화능줄기세포 유래 심근세포를 이용한 SARS-CoV-2 바이러스 대상 후보 약물의 심근세포 독성 평가용 조성물 및 이를 이용한 심근세포 독성 평가 방법 |
| US12173322B2 (en) | 2020-12-09 | 2024-12-24 | The University Of Queensland | Genome-edited induced pluripotent stem cells, and cells derived therefrom, and uses thereof |
| WO2023183371A2 (en) * | 2022-03-22 | 2023-09-28 | The Trustees Of Columbia University In The City Of New York | Engineered heart tissue model of restrictive cardiomyopathy for drug discovery |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160017268A1 (en) * | 2013-03-15 | 2016-01-21 | University Of Washington Through Its Center For Commercialization | Device and methods comprising microelectrode arrays for electroconductive cells |
| US9624471B2 (en) * | 2013-06-12 | 2017-04-18 | University Of Washington Through Its Center For Commercialization | Methods for maturing cardiomyocytes and uses thereof |
| US10844354B2 (en) * | 2014-06-06 | 2020-11-24 | Ncardia B.V. | Cardiomyocyte maturation |
| CN106148284A (zh) * | 2015-03-23 | 2016-11-23 | 苏州博瑞斯坦生物医药有限公司 | 小分子定向组织和器官再生的多能人类干细胞技术、方法和产品 |
-
2018
- 2018-08-16 US US16/638,693 patent/US20200224168A1/en not_active Abandoned
- 2018-08-16 JP JP2020509099A patent/JP2020535791A/ja active Pending
- 2018-08-16 KR KR1020207006161A patent/KR20200039707A/ko not_active Withdrawn
- 2018-08-16 CN CN201880065554.6A patent/CN111246863A/zh active Pending
- 2018-08-16 EP EP18845846.7A patent/EP3664821A4/en not_active Withdrawn
- 2018-08-16 WO PCT/IB2018/056169 patent/WO2019035032A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535791A5 (enExample) | ||
| Meier et al. | Epicardioid single-cell genomics uncovers principles of human epicardium biology in heart development and disease | |
| Funakoshi et al. | Recent progress of iPSC technology in cardiac diseases | |
| Kita-Matsuo et al. | Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes | |
| Lyon et al. | Connexin defects underlie arrhythmogenic right ventricular cardiomyopathy in a novel mouse model | |
| JP6388537B2 (ja) | 患者由来の人工多能性幹細胞由来の心筋細胞および使用方法 | |
| KR102634265B1 (ko) | 심근세포 성숙 | |
| Leone et al. | Advances in heart regeneration based on cardiomyocyte proliferation and regenerative potential of binucleated cardiomyocytes and polyploidization | |
| Yang et al. | Concise review: cardiac disease modeling using induced pluripotent stem cells | |
| Ghosheh et al. | Electro-metabolic coupling in multi-chambered vascularized human cardiac organoids | |
| Rupert et al. | Human cardiac fibroblast number and activation state modulate electromechanical function of hiPSC‐cardiomyocytes in engineered myocardium | |
| JP2006523091A5 (enExample) | ||
| JP2014502847A (ja) | 腫瘍細胞及び組織培養 | |
| Zawada et al. | Retinoic acid signaling modulation guides in vitro specification of human heart field-specific progenitor pools | |
| ES2701704T3 (es) | Sistemas de ensayo tisulares funcionales no invasivos in vitro | |
| White et al. | Embryonic stem cells form an organized, functional cardiac conduction system in vitro | |
| US20200224168A1 (en) | Compositions and methods for enhancing maturation states of healthy and diseased cardiomyocytes | |
| Pesl et al. | Phenotypic assays for analyses of pluripotent stem cell–derived cardiomyocytes | |
| Di Nardo et al. | Cardiac progenitor cells: potency and control | |
| Lluri et al. | Hematopoietic progenitors are required for proper development of coronary vasculature | |
| Rota et al. | Aging effects on cardiac progenitor cell physiology | |
| US20190185816A1 (en) | Cardiac microtissue and uses thereof | |
| ES2584428T3 (es) | Modelado de tejidos en un sistema de células madre embrionarias (ES) | |
| KR102740042B1 (ko) | 인간 전분화능 줄기세포로 유래된 심장 오가노이드 제조방법, 효능 및 독성 평가 기술 | |
| Feaster et al. | Nonclinical evaluation of chronic cardiac contractility modulation on 3D human engineered cardiac tissues |